Success Metrics

Clinical Success Rate
20.0%

Based on 1 completed trials

Completion Rate
20%(1/5)
Active Trials
0(0%)
Results Posted
200%(2 trials)
Terminated
4(80%)

Phase Distribution

Ph phase_2
1
20%
Ph phase_1
2
40%
Ph phase_3
2
40%

Phase Distribution

2

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
2(40.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

20.0%

1 of 5 finished

Non-Completion Rate

80.0%

4 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(1)
Terminated(4)

Detailed Status

Terminated4
Completed1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
20.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (40.0%)
Phase 21 (20.0%)
Phase 32 (40.0%)

Trials by Status

terminated480%
completed120%

Recent Activity

0 active trials
Showing 5 of 5
terminatedphase_3

Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease.

NCT03051607
terminatedphase_3

Safety and Efficacy Study of Tozadenant to Treat End of Dose Wearing Off in Parkinson's Patients

NCT02453386
terminatedphase_1

A Study to Determine the Abuse Potential of Tozadenant Relative to D-Amphetamine and Placebo When Administered Orally in Healthy, Non-Dependent, Recreational Polydrug Users

NCT03200080
terminatedphase_1

Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Tozadenant

NCT03212313
completedphase_2

Study to Evaluate SYN115 in Parkinson's Disease

NCT00605553

Clinical Trials (5)

Showing 5 of 5 trials
NCT03051607Phase 3

Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease.

Terminated
NCT02453386Phase 3

Safety and Efficacy Study of Tozadenant to Treat End of Dose Wearing Off in Parkinson's Patients

Terminated
NCT03200080Phase 1

A Study to Determine the Abuse Potential of Tozadenant Relative to D-Amphetamine and Placebo When Administered Orally in Healthy, Non-Dependent, Recreational Polydrug Users

Terminated
NCT03212313Phase 1

Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Tozadenant

Terminated
NCT00605553Phase 2

Study to Evaluate SYN115 in Parkinson's Disease

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5